Quanterix Announces Commercialization Of p-Tau 217 Test Kit
Portfolio Pulse from Benzinga Newsdesk
Quanterix Corporation has announced the commercialization of its Simoa® p-Tau 217 Planar Kit, a blood test kit for Alzheimer's Disease, using antibody technology licensed from Eli Lilly. This marks a significant step in expanding access to Alzheimer's diagnostics.
September 30, 2024 | 8:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Eli Lilly's licensed antibody technology is being used in Quanterix's new Alzheimer's test kit, potentially increasing the visibility and application of Lilly's technology in the diagnostics market.
Eli Lilly's technology being used in Quanterix's new product could enhance the perception of Lilly's innovation in the diagnostics field, potentially leading to increased interest and partnerships.
CONFIDENCE 85
IMPORTANCE 60
RELEVANCE 50
POSITIVE IMPACT
Quanterix has launched the Simoa® p-Tau 217 Planar Kit, expanding its Alzheimer's Disease diagnostics offerings. This commercialization could enhance Quanterix's market position in the AD diagnostics space.
The commercialization of the p-Tau 217 test kit represents a significant product expansion for Quanterix, potentially increasing its market share in Alzheimer's diagnostics. The use of Eli Lilly's licensed technology adds credibility and potential demand for the product.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100